Isabelle Ollivier-Hourmand, Yohann Repesse, Pierre Nahon, Cendrine Chaffaut, Thông Dao, Thi Thu Nga Nguyen, Patrick Marcellin, Dominique Roulot, Victor De Ledinghen, Stanislas Pol, Dominique Guyader, Isabelle Archambeaud, Fabien Zoulim, Frédéric Oberti, Albert Tran, Jean-Pierre Bronowicki, Louis D'Alteroche, Denis Ouzan, Jean-Marie Peron, Jean-Pierre Zarski, Marc Bourliere, Dominique Larrey, Alexandre Louvet, Paul Cales, Armand Abergel, Philippe Mathurin, Ariane Mallat, Jean-Frederic Blanc, Eric Nguyen-Khac, Ghassan Riachi, Laurent Alric, Lawrence Serfaty, Teresa Antonini, Christophe Moreno, Pierre Attali, Dominique Thabut, Christophe Pilette, Jean-Didier Grange, Christine Silvain, Nicolas Carbonell, Brigitte Bernard-Chabert, Odile Goria, Claire Wartelle, Romain Moirand, Christos Christidis, Gabriel Perlemuter, Violaine Ozenne, Jean Henrion, Sophie Hillaire, Vincent Di Martino, Xavier Amiot, Angela Sutton, Nathalie Barget, Sylvie Chevret, Nathalie Ganne-Carrie
Journal: Liver international : official journal of the International Association for the Study of the Liver 2022;42(6):1386-1400
PMID: 35025128
BACKGROUND AND AIMS
Non-O blood group promotes deep vein thrombosis and liver fibrosis in both general population and hepatitis C. We aimed to evaluate the influence of Non-O group on the outcome of Child-Pugh A cirrhotic patients.
METHODS
We used two prospective cohorts of Child-Pugh A cirrhosis due to either alcohol or viral hepatitis. Primary end point was the cumulated incidence of 'Decompensation' at 3 years, defined as the occurrence of ascites , hydrothorax, encephalopathy, gastrointestinal bleeding related to portal hypertension, or bilirubin >45 μmol/L. Secondary end points were the cumulated incidences of (1) 'Disease Progression' including a « decompensation» or « the occurrence of one or more parameters » among: prothrombin time (PT) <45%, albumin <28 g/L, Child-Pugh worsening (B or C vs A or B, C vs B), hepatorenal syndrome, and hepato-pulmonary syndrome, (2) other events such as non-malignant portal vein thrombosis (nmPVT), and (3) overall survival.
RESULTS
Patients (n = 1789; 59.9% Non-O group; 40.1% group O) were followed during a median of 65.4 months. At 3 years cumulated incidence of Decompensation was 8.3% in Non-O group and 7.2% in group O (P = .27). Cumulated incidence of Disease Progression was 20.7% in Non-O group and 18.9% in group O (P = .26). Cumulated incidence of nmPVT was 2.7% in Non-O group and 2.8% in group O (P = .05). At 3 years overall survival was 92.4% in Non-O group and 93.4% in group O (P = 1).
CONCLUSION
Non-O group does not influence disease outcome in Child-Pugh A cirrhotic patients. Clinicals trial number NCT03342170.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
© Copyright 2026, Nutrition Evidence
NED wishes to thank the following organisations for their support:
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.